Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Study to Evaluate the Safety of Subunit Influenza Vaccine in People Aged 6 Months and Older

6. november 2026 oppdatert av: Ab&B Bio-tech Co., Ltd.JS

A Post-Marketing, Open-Label, Single-Arm Observational Study to Evaluate the Safety and Vaccination Influencing Factors of Subunit Influenza Vaccine in Individuals Aged 6 Months and Older

This is a post-marketing, prospective observational study to evaluate the safety of a subunit influenza vaccine and the factors influencing influenza vaccination in individuals aged 6 months and older. A total of 7,000 vaccinated participants will be divided into Subgroup A (1,000 participants, active surveillance) and Subgroup B (6,000 participants, passive surveillance), and monitored for adverse events and serious adverse events within 28 days after vaccination. Participants in Subgroup A will additionally complete an electronic questionnaire on their knowledge of influenza and factors influencing their vaccination decisions.

Studieoversikt

Status

Rekruttering

Forhold

Detaljert beskrivelse

Study Objectives The primary objectives of this study are: (1) to evaluate the safety of the subunit influenza vaccine in individuals aged 6 months and older after vaccination, in order to assess the occurrence of adverse reactions; and (2) to investigate vaccinated individuals' knowledge of influenza and influenza vaccine, and the factors influencing their vaccination decisions.Study Design This is a post-marketing, prospective, open-label, single-arm observational study. Participants who have already received the subunit influenza vaccine at the study site will be enrolled and divided into two subgroups according to the surveillance mode: Subgroup A (1,000 participants) under active surveillance, and Subgroup B (6,000 participants) under passive surveillance. All participants will be observed for 30 minutes after vaccination and monitored for adverse events (AEs) and serious adverse events (SAEs) within 28 days after vaccination.Study Population Individuals aged 6 months and older who have received the subunit influenza vaccine at the study site and are able to comply with the study requirements. Participants with allergy to any vaccine component (including excipients, formaldehyde, or Triton N-101), acute illness, severe chronic disease, acute exacerbation of chronic disease, fever, uncontrolled epilepsy, other progressive neurological diseases, a history of Guillain-Barré syndrome, or a history of severe adverse reactions to previous influenza vaccination will be excluded.Safety Monitoring All participants will remain under observation for 30 minutes immediately after vaccination. The occurrence of AEs and SAEs within 28 days post-vaccination will be collected and recorded, including solicited local reactions (pain, swelling, erythema, pruritus, induration, ecchymosis) and systemic events (fever, cough, headache, rhinorrhea, fatigue, myalgia, arthralgia, gastrointestinal symptoms, rash, etc.). Subgroup A participants will receive a telephone follow-up on Day 28, while Subgroup B participants will self-report AEs to investigators during the same period. Any SAE will be reported in accordance with applicable regulations.Influencing Factor Survey Participants in Subgroup A will complete an electronic questionnaire during the post-vaccination observation period (by themselves if aged 18 years or older, or by their guardians if under 18), collecting demographic information, medical and vaccination history, and their knowledge of influenza and influenza vaccine, as well as the factors influencing their vaccination decisions.

Studietype

Observasjonsmessig

Registrering (Antatt)

7000

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Jiangxi
      • Ganzhou, Jiangxi, Kina
        • Rekruttering
        • Ganzhou Center for Disease Control and Prevention (Ganzhou Health Comprehensive Supervision and Law Enforcement Bureau)
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

6 måneder og eldre (Barn, Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Healthy individuals aged 6 months and older who have received the subunit influenza vaccine at the study site and meet the eligibility criteria.

Beskrivelse

Inclusion Criteria:

  1. Aged 6 months and older;
  2. Have received the subunit influenza vaccine at the study site;
  3. Able to comply with the requirements of the study protocol

Exclusion Criteria:

  1. Allergy to any component of the vaccine, including excipients, formaldehyde, or the splitting agent Triton N-101;
  2. Acute illness, severe chronic disease, acute exacerbation of chronic disease, or fever;
  3. Uncontrolled epilepsy or other progressive neurological diseases, or a history of Guillain-Barré syndrome;
  4. History of severe adverse reactions following previous influenza vaccination;
  5. Any other condition deemed by the investigator to be unsuitable for enrollment.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Group A

Active Surveillance Group

Participants will receive one dose of Subunit Influenza Vaccine

Group B

Passive Surveillance Group

Participants will receive one dose of Subunit Influenza Vaccine

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Occurrence of AEs and ADRs
Tidsramme: Within 28 days post-vaccination

Adverse events and adverse drug reactions occurring within 28 days of vaccination will be recorded, including solicited local and systemic reactions.

Within 28 days post-vaccination
Occurrence of SAEs
Tidsramme: Within 28 days post-vaccination

Serious adverse events occurring within 28 days of vaccination will be recorded.

Within 28 days post-vaccination

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

4. september 2026

Primær fullføring (Antatt)

31. mars 2027

Studiet fullført (Antatt)

30. september 2027

Datoer for studieregistrering

Først innsendt

6. november 2026

Først innsendt som oppfylte QC-kriteriene

6. november 2026

Først lagt ut (Faktiske)

12. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

12. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

6. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere